Advanced search
Publication Cover
Journal of Market Access & Health Policy Volume 5, 2017 - Issue 1
Journal homepage
1,291
Views
5
CrossRef citations to date
0
Altmetric
Transferred Article

Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome

Clément FrançoisHealth Economics and Outcomes Research, Lundbeck, LLC, Deerfield, IL, USAView further author information
,
John M. SternDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USAView further author information
,
Augustina OgbonnayaScientific Consulting, Xcenda, LLC, Palm Harbor, FL, USAView further author information
,
Tasneem LokhandwalaScientific Consulting, Xcenda, LLC, Palm Harbor, FL, USAORCID Iconhttp://orcid.org/0000-0002-1983-9557View further author information
ORCID Icon,
Pamela Landsman-BlumbergScientific Consulting, Xcenda, LLC, Palm Harbor, FL, USAView further author information
,
Amy DuhigScientific Consulting, Xcenda, LLC, Palm Harbor, FL, USACorrespondence[email protected]
View further author information
,
Vivienne ShenHealth Economics and Outcomes Research, Lundbeck, LLC, Deerfield, IL, USAView further author information
&
Robin TanScientific Consulting, Xcenda, LLC, Palm Harbor, FL, USAView further author information
 show all
Article: 1318691 | Received 22 Dec 2016, Accepted 31 Mar 2017, Published online: 19 May 2017

References

  • Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):1–16.
  • Camfield PR. Definition and natural history of Lennox-Gastaut syndrome. Epilepsia. 2011;52(Suppl 5):3–9.
  • Crumrine PK. Lennox-Gastaut syndrome. J Child Neurol. 2002;17(Suppl 1):S70–S75.
  • Markand ON. Lennox-Gastaut syndrome (childhood epileptic encephalopathy). J Clin Neurophysiol. 2003;20(6):426–441.
  • van Rijckevorsel K. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat. 2008;4(6):1001–1019.
  • Camfield P, Camfield C. Epileptic syndromes in childhood: clinical features, outcomes, and treatment. Epilepsia. 2002;43(Suppl 3):27–32.
  • Gallop K, Wild D, Nixon A, et al. Impact of Lennox-Gastaut Syndrome (LGS) on health-related quality of life (HRQL) of patients and caregivers: literature review. Seizure. 2009;18(8):554–558.
  • Montouris GD, Wheless JW, Glauser TA. The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome. Epilepsia. 2014;55(Suppl 4):10–20.
  • Sugai K. Clobazam as a new antiepileptic drug and clorazepate dipotassium as an alternative antiepileptic drug in Japan. Epilepsia. 2004;45(Suppl 8):20–25.
  • Ng YT, Conry J, Mitchell WG, et al. Clobazam is equally safe and efficacious for seizures associated with Lennox-Gastaut syndrome across different age groups: post hoc analyses of short- and long-term clinical trial results. Epilepsy Behav. 2015;46:221–226.
  • Clements KM, Skornicki M, O’Sullivan AK. Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome. Epilepsy Behav. 2013;29(1):184–189.
  • Skornicki M, Clements KM, O’Sullivan AK. Budget impact analysis of antiepileptic drugs for Lennox-Gastaut syndrome. J Manag Care Spec Pharm. 2014;20(4):400–406.
  • 2015 Truven Health Analytics MarketScan® Research Databases. Commercial claims and encounters, Medicare supplemental and coordination of benefits, and Medicaid databases data dictionary [subscription access]; [ cited 2016 Apr 8]. Available from: http://truvenhealth.com/your-healthcare-focus/analytic-research/marketscan-research-databases
  • Stürmer T, Wyss R, Glynn RJ, et al. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med. 2014;275(6):570–580.
  • Brodie MJ, Chung S, Wade A, et al. Clobazam and clonazepam use in epilepsy: results from a UK database incident user cohort study. Epilepsy Res. 2016;123:68–74.
  • Gao L, Xia L, Pan SQ, et al. Burden of epilepsy: a prevalence-based cost of illness study of direct, indirect and intangible costs for epilepsy. Epilepsy Res. 2015;110:146–156.
  • Gianfrancesco F, Wang RH, Mahmoud R, et al. Methods for claims-based pharmacoeconomic studies in psychosis. Pharmacoeconomics. 2002;20(8):499–511.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.